Covid Analysis @CovidAnalysis Twitter profile | Pikagi

Pikagi

Covid Analysis

@CovidAnalysis

9,788

Followers

45

Following

70

Media

365

Statuses

Real-time analysis of 4,700+ COVID-19 treatment studies for 95 treatments.

Joined June 2020

Don't wanna be here? Send us removal request.

Pinned Tweet

@CovidAnalysis

Covid Analysis

6 days

@GidMK @RetractionWatch Can you explain why the largest prophylaxis RCT showing efficacy for symptomatic PCR+ cases (p = 0.00024) is "gibberish" that needs to be hidden? Why is the meta analysis of RCTs showing 42% lower symptomatic PCR+ cases (p = 0.0006) "gibberish" that needs to be hidden? Why is

Tweet media one

Tweet media two

5

3

7

Last Seen Profiles

@UgurWeb3

@Soenyy_

@Shiv_NMapp

@bokeplokalmalam

@CdPlatformu07

@MaryFabulous3

@SuigetsuLAD

@gparaj

@Sage_Solus

@teruk1_

@chupacabra1003

@theWhaleAlert

@3rdPerson_IZ

@Aladdin48726620

@fiji_daze

@CGNCmedia

@PeeGoing

@Maurici85207186

@wowfactormom6

@stw_pdg

@ReineEUW

@dinojacob_

@Mohv_913

@ineedfoodbro

@CMOSCSC

@AgusMau16

@canizmoure

@VimalAgnih71921

@piraprimrose

@YuuuH

@radiohead

@Sparklygoblin

@graygoo400sol3

@ChuckDalldorf

@c_s_30

@trhk_kbdng

@CovidAnalysis

Covid Analysis

4 years

Countries have adopted or declined early treatment, forming a country-randomized controlled trial with over 2.5B people. Treatment countries show a significantly lower death rate. #hcqtrial

53

519

831

@CovidAnalysis

Covid Analysis

7 months

PRINCIPLE trial: significantly improved recovery and significantly lower risk of long COVID with ivermectin, even with very late treatment and poor administration. This is despite being the most clearly designed to fail study (compare the treatment delay, population, treatment

Tweet media one

70

459

897

@CovidAnalysis

Covid Analysis

4 years

HCQ early treatment studies are now 20 of 20 with positive results. 63% reduction in the effect measured (death, hospitalization, etc.), RR 0.37 [0.29-0.47].

Tweet card media

Szente Fonseca: Risk of Hospitalization for Covid-19 Outpatients Treated with Various Drug Regimens...

Szente Fonseca, 717 patient HCQ early treatment study: 64% lower hospitalization (p=0.0008). 64% lower hospitalization with HCQ. Retrospective 717 patients in..

26

383

766

@CovidAnalysis

Covid Analysis

1 year

When we were censored, 11 studies showed that vitamin D reduces risk for COVID-19 (p<0.001). Now there are 111 (p<0.0000000001). Here is a timeline of the clinical evidence for vitamin D and acetaminophen / paracetamol.

Tweet media one

18

268

717

@CovidAnalysis

Covid Analysis

4 years

HCQ is effective for COVID-19 when used early: analysis of 115 studies. The probability that an ineffective treatment generated results as positive as the 115 studies to date is estimated to be 1 in 20 million (p = 0.000000049). #HCQ115

17

163

257

@CovidAnalysis

Covid Analysis

4 years

Is hydroxychloroquine effective for COVID-19? A video history of HCQ studies.

9

99

231

@CovidAnalysis

Covid Analysis

4 years

HCQ studies in North America are 3.6 times more likely to report negative effects compared to the rest of the world, 47.4% vs. 13.1%, p = 0.000005 (as of 12/21). Why?

18

68

213

@CovidAnalysis

Covid Analysis

4 years

1 in 824 million. 132 HCQ studies. The probability that the results are from an ineffective treatment has reduced to 1 in 824 million (p = 0.0000000012).

6

92

218

@CovidAnalysis

Covid Analysis

4 years

70% lower mortality with vitamin D supplementation. Analysis of 98 PCR+ nursing home residents in Italy, mean age 90, p = 0.04.

Tweet card media

Cangiano: Mortality in an Italian nursing home during COVID-19 pandemic: correlation with gender,...

Cangiano, 98 patient vitamin D prophylaxis study: 70% lower mortality (p=0.04). 70% lower mortality with vitamin D supplementation. Analysis of 98 PCR+..

2

79

208

@CovidAnalysis

Covid Analysis

4 years

COVID-19 treatment analysis: #COVID #COVID19 #coronavirus #covidtreatment #treatcovid

39

116

169

@CovidAnalysis

Covid Analysis

4 years

Now 11 vitamin D COVID-19 treatment studies, meta analysis version 2: treatment - 75% improvement, p = 0.0002, 11 studies sufficiency - 58% improvement, p < 0.0001, 24 studies

6

92

201

@CovidAnalysis

Covid Analysis

4 years

We suddenly started receiving many malicious personal, doxxing, hacking, and DDoS attacks. We may be unavailable for some time while we work on forensic analysis and personal safety.

16

47

175

@CovidAnalysis

Covid Analysis

4 years

Ivermectin is effective for COVID-19. 25 studies including 10 RCTs. Early treatment - ↓87%, p=0.0005 PrEP - ↓98%, p=0.065 PEP - ↓90%, p<0.0001 1 in 34 million probability that the results are from an ineffective treatment (p=0.00000003).

2

96

184

@CovidAnalysis

Covid Analysis

6 months

71% lower mortality with HCQ, p = 0.03. One of the 39 missing HCQ RCTs has been published 1,212 days after the end of the trial. This trial had no control group, comparing different treatments and combinations. The HCQ arms had 71% lower mortality than the non-HCQ arms, p =

Tweet media one

15

79

189

@CovidAnalysis

Covid Analysis

4 years

100% of the 16 ivermectin treatment studies report positive effects.

5

84

158

@CovidAnalysis

Covid Analysis

7 months

Comparison of the Oxford ivermectin and molnupiravir trials. Same chief investigator, different goal.

Tweet media one

9

80

162

@CovidAnalysis

Covid Analysis

1 year

Ex vivo analysis of HCQ showing preferential SARS-CoV-2 protection for early target cell types in the lung, consistent with the increased efficacy seen with early treatment. Chaudhary et al., Scientific Reports, Aug 2023, doi:10.1038/s41598-023-39941-6. Authors analyze various

Tweet media one

6

83

160

@CovidAnalysis

Covid Analysis

4 years

Early treatment results in 84% lower hospitalization and 80% lower death - hospitalization OR 0.16 (p<0.001), death OR 0.2 (p=0.16). #COVID19 #ZelenkoProtocol @zev_dr

7

95

115

@CovidAnalysis

Covid Analysis

4 years

Open letter from over 100 scientists & doctors recommending vitamin D levels >75 nmol/L, 2000-4000IU daily supplementation (in the absence of testing), and measurement/treatment in hospitalized patients. #VitaminDforAll

Tweet card media

VitaminDForAll: Over 100 Scientists, Doctors, & Leading Authorities Call For Increased Vitamin D...

Over 100 scientists and doctors call for efforts to increase vitamin D levels. Recommendations include reaching 75 nmol/L serum levels, 2000-4000IU daily..

4

45

120

@CovidAnalysis

Covid Analysis

4 years

Vitamin D meta analysis for COVID-19 treatment - 76% improvement, p = 0.00049, 10 studies sufficiency - 58% improvement, p < 0.0001, 24 studies

3

57

119

@CovidAnalysis

Covid Analysis

7 months

PRINCIPLE trial ivermectin arm:

Tweet card media

PRINCIPLE: significantly improved recovery and lower long COVID with ivermectin

Significantly improved recovery and significantly lower risk of long COVID with ivermectin (PRINCIPLE trial).

7

42

133

@CovidAnalysis

Covid Analysis

4 years

Ivermectin is very effective for COVID-19. Analysis of the 21 studies to date. Early treatment - ↓91% - RR 0.09 p = 0.002 Late treatment - ↓60% - RR 0.40 p = 0.0004 PrEP - ↓98% - RR 0.02 p = 0.065 PEP - ↓87% - RR 0.13 p = 0.0003

11

66

114

@CovidAnalysis

Covid Analysis

4 years

73% lower mortality with HCQ. Analysis of 98 PCR+ nursing home residents in Italy, mean age 90, p = 0.03. Subject to confounding by contraindication.

Tweet card media

Cangiano: Mortality in an Italian nursing home during COVID-19 pandemic: correlation with gender,...

Cangiano, 98 patient HCQ late treatment study: 73% lower mortality (p=0.03). 73% lower mortality with HCQ. Analysis of 98 PCR+ nursing home residents in Italy..

1

39

105

@CovidAnalysis

Covid Analysis

7 months

36% lower long COVID with ivermectin. Page 358 in the appendix of the PRINCIPLE ivermectin paper shows: 36% lower ongoing persistent COVID-19 specific symptoms (p<0.0001) when combining the individual symptom results. The paper reports a 28% reduction (p=0.015), not mentioned

Tweet media one

15

39

111

@CovidAnalysis

Covid Analysis

4 years

HCQ 24 of 24 for positive effects in early treatment studies. 65% improvement from random effects meta-analysis, RR 0.35 [0.27‑0.46], p < 0.0001

6

34

79

@CovidAnalysis

Covid Analysis

4 years

80% lower mortality with high-dose vitamin D booster therapy. Retrospective 986 hospitalized patients in the UK. Primary cohort aOR 0.13, p < 0.001. Validation cohort aOR 0.38, p = 0.018.

Ling: High-Dose Cholecalciferol Booster Therapy is Associated with a Reduced Risk of Mortality in...

Ling, 523 patient vitamin D late treatment study: 80% lower mortality (p=0.001). 80% lower mortality with cholecalciferol booster therapy. Retrospective 986..

3

45

95

@CovidAnalysis

Covid Analysis

4 years

1 in 2 billion probability that the results of the 134 HCQ studies to date are from an ineffective treatment (p = 0.00000000052). Who wants to make a bet with us?

Tweet card media

Is hydroxychloroquine effective for COVID-19? A video history of the...

A video history of the 134 HCQ studies to date.The probability that the results are from an ineffective treatment is estimated to be 1 in 2 billion (p = 0.00...

www.youtube.com

5

37

103

@CovidAnalysis

Covid Analysis

4 years

10 ivermectin Randomized Controlled Trials. 100% report positive effects. 70% improvement in random effects meta-analysis. Relative risk RR 0.30 [0.16‑0.56] p = 0.0001

4

43

101

@CovidAnalysis

Covid Analysis

4 years

1/ NEJM PEP study: "HCQ did not prevent illness compatible with COVID-19 when initiated within 4 days". Let's take a look. The main result reported is not statistically significant, but indicates treatment is more likely to be effective than not:

Tweet media one

6

32

86

@CovidAnalysis

Covid Analysis

7 months

Increased mutagenesis and viral persistence with molnupiravir:

Tweet card media

Standing: Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in...

Standing, 592 patient molnupiravir early treatment RCT: 103% worse viral clearance (p=0.33). PANORAMIC virology-sub-study showing increased viral persistence..

2

28

88

@CovidAnalysis

Covid Analysis

4 years

Now 178 HCQ COVID-19 controlled studies, meta analysis version 42: early treatment - 65% improvement, p < 0.0001 all studies - 34% improvement, p < 0.0001 All early treatment studies show positive effects.

1

39

86

@CovidAnalysis

Covid Analysis

4 years

The Guardian: "No clinical trials have yet found in favour of using hydroxychloroquine against Covid-19" Actually 107 of 139 studies show positive effects for HCQ. 22 of 22 early treatment studies show positive effects for HCQ.

French professor faces disciplinary case over hydroxychloroquine claims

Didier Raoult stands accused of touting drug as a coronavirus treatment without evidence

www.theguardian.com

6

39

74

@CovidAnalysis

Covid Analysis

4 years

@drdavidsamadi Vitamin D meta analysis for COVID-19 treatment - 76% improvement, p = 0.00049, 10 studies sufficiency - 58% improvement, p < 0.0001, 24 studies

2

27

52

@CovidAnalysis

Covid Analysis

4 years

91% reduction in COVID-19 with ivermectin prophylaxis. 118 healthcare workers in Bangladesh, 58 receiving ivermectin 12mg monthly, RR 0.094, p < 0.0001.

Tweet card media

Alam: Ivermectin as Pre-exposure Prophylaxis for COVID-19 among Healthcare Providers in a Selected...

Alam, 118 patient ivermectin prophylaxis study: 91% fewer cases (p<0.0001). 91% reduction in COVID-19 cases with ivermectin prophylaxis. 118 healthcare..

3

38

71

@CovidAnalysis

Covid Analysis

4 years

1 in 69 million. 126 HCQ studies. The probability that the results are from an ineffective treatment is estimated to be 1 in 69 million (p = 0.000000015). All early treatment studies report a positive effect. #hcqmeta

3

39

68

@CovidAnalysis

Covid Analysis

4 years

64% mortality reduction with HCQ, p = 0.012. Early treatment in ambulatory fever clinics in Saudi Arabia. 5,541 patients. #c19study

Sulaiman: The Effect of Early Hydroxychloroquine-based Therapy in COVID-19 Patients in Ambulatory...

Sulaiman, 7,892 patient HCQ early treatment study: 64% lower mortality (p=0.01), 44% lower combined mortality/ICU admission (p=0.02), 37% lower ICU admission ..

5

36

71

@CovidAnalysis

Covid Analysis

4 years

30% lower pneumonia with HCQ prophylaxis, but ↑PCR+. ↑PCR+ may be due to survey bias, treatment self-selection, variable regimens. Improvement on severity may be related to higher HCQ lung conc., binary PCR not distinguishing replication-competence.

Tweet card media

Gönenli: Analysis of the Prophylactic use of Hydroxychloroquine at the Beginning of the COVID-19...

Gönenli, 564 patient HCQ prophylaxis study: 30% lower progression (p=0.77) and 19% more cases (p=0.58). Small prophylaxis survey showing lower, but not..

1

17

70

@CovidAnalysis

Covid Analysis

4 years

65% reduction in cases with HCQ within 3 days of exposure, RR 0.35, p=0.043. Analysis of Boulware et al. PEP data. Authors obtained shipping delay information to determine patients that received the medication within 3 days.

Tweet media one

3

30

65

@CovidAnalysis

Covid Analysis

1 year

38 COVID-19 HCQ RCTs have not reported their results. 29 are over 2 years late. Early treatment and prophylaxis RCTs are 3 times more likely to have not reported results compared to late treatment, consistent with the higher prevalence of positive trials for early treatment and

Tweet media one

2

25

67

@CovidAnalysis

Covid Analysis

4 years

47% lower mortality with HCQ/CQ. Retrospective 5,847 patients in Canada, China, Cuba, Ecuador, Germany, Italy and Spain. Multivariable Cox regression HCQ/CQ mortality hazard ratio HR 0.53, p < 0.001.

Signes-Costa: Prevalence and 30-day mortality in hospitalized patients with COVID-19 and prior lung...

Signes-Costa, 5,847 patient HCQ late treatment study: 47% lower mortality (p=0.0005). 47% lower mortality with HCQ/CQ. Retrospective 1,271 patients with lung..

2

21

53

@CovidAnalysis

Covid Analysis

4 years

100% reduction in both hospitalization (p=0.01) and 14 day PCR+ (p=0.001) using early treatment with HCQ+AZ+zinc. 0/0 of 33 hosp./14 day PCR+ with treatment vs. 2/3 of 5 control. Simova et al., doi:10.1016/j.nmni.2020.100813

Tweet card media

Simova: Hydroxychloroquine for prophylaxis and treatment of COVID-19 in health care workers [HCQ]

Simova, 38 patient HCQ early treatment study: 94% lower hospitalization (p=0.01) and 96% improved viral clearance (p=0.001). 100% reduction in hospitalization..

3

23

48

@CovidAnalysis

Covid Analysis

4 years

Significantly lower mortality, propensity matched HR 0.49, p=0.009. Michigan 2,541 patients retrospective. #COVID19

Arshad: Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized...

Arshad, 2,541 patient HCQ late treatment study: 51% lower mortality (p=0.009). HCQ decreases mortality from 26.4% to 13.5% (HCQ) or 20.1% (HCQ+AZ). Propensity..

1

26

37

@CovidAnalysis

Covid Analysis

4 years

85% lower disease progression with early use of HCQ. Retrospective 616 patients in China showing adjusted progression HR 0.15, p = 0.006.

Tweet card media

Su: Efficacy of early hydroxychloroquine treatment in preventing COVID-19 pneumonia aggravation,...

Su, HCQ early treatment study: 85% lower progression (p=0.006), 24% faster improvement (p=0.02), and 36% improved viral clearance (p=0.001). 85% lower disease..

2

22

53

@CovidAnalysis

Covid Analysis

1 year

Details for vitamin D:

Tweet card media

Vitamin D for COVID-19: real-time meta analysis of 325 studies (122 treatment studies and 203...

325 vitamin D COVID-19 studies. 37% improvement for treatment studies, p < 0.0001. 52% improvement for sufficiency studies, p < 0.0001.

1

15

52

@CovidAnalysis

Covid Analysis

4 years

Very small 24 patient ivermectin RCT showing significantly faster viral load reduction and symptom improvement. 95% lower viral load mid-recovery at day 7 56% lower probability of symptoms at day 28

1

21

46

@CovidAnalysis

Covid Analysis

7 months

119 controlled clinical studies of vitamin D treatment for COVID-19. What do we know? ✅Confirmed to reduce risk October 2020 ✅Confirmed via RCTs September 2021 (almost 1 year delay) ❌NIH: “insufficient evidence”, but they only reference 14% of RCTs ✅Calcifediol, calcitriol &

Tweet media one

2

20

53

@CovidAnalysis

Covid Analysis

4 years

1 in 6 trillion probability that the 152 HCQ study results are from an ineffective treatment. Many have gone silent, but some are still holding on to the 1 in 6 trillion chance that their advice was not harmful.

Tweet card media

Is hydroxychloroquine effective for COVID-19? A video history of the...

A video history of the 152 HCQ studies to date.The probability that the results are from an ineffective treatment is estimated to be 1 in 6 trillion (p = 0.0...

www.youtube.com

3

12

41

@CovidAnalysis

Covid Analysis

4 years

Estimated number of human lives lost from incorrect advice on HCQ. 100% of early treatment studies report a positive effect, with a 63% reduction in the effect measured in a random-effects meta-analysis, RR 0.37 [0.29-0.47].

2

24

40

@CovidAnalysis

Covid Analysis

4 years

87% lower mortality with ivermectin. Retrospective 976 hospitalized patients, 34 treated with ivermectin, showing mortality relative risk RR 0.13, p=0.04. Budhiraja et al., medRxiv, doi:10.1101/2020.11.16.20232223

Tweet card media

Budhiraja: Clinical Profile of First 1000 COVID-19 Cases Admitted at Tertiary Care Hospitals and...

Budhiraja, 976 patient ivermectin late treatment study: 99% lower mortality (p=0.04). Retrospective 976 hospitalized patients with 34 treated with ivermectin..

0

14

37

@CovidAnalysis

Covid Analysis

4 years

Small 95 patient study in Pakistan adding ivermectin to SOC for outpatients with mild/moderate suspected COVID-19, showing significantly faster resolution of fever with ivermectin.

1

17

37

@CovidAnalysis

Covid Analysis

1 year

Analysis of the 402 clinical studies to date, showing significantly better results with early treatment:

4

17

39

@CovidAnalysis

Covid Analysis

4 years

46% lower mortality with HCQ. Small early terminated late stage RCT. Mortality at 28 days RR 0.54 [0.21-1.42]. If not stopped early and the trend continued, stat. significance would be reached on 28 day mortality after ~550 patients (1,300 planned).

1

9

33

@CovidAnalysis

Covid Analysis

10 months

New study: physical activity, good sleep, and a healthy diet significantly lower COVID-19 risk. Analysis of 5,197 Greek adults over 65. After adjustment for confounding factors, COVID-19 was independently associated with poor sleep, low physical activity, low Mediterranean diet

Tweet media one

Tweet media two

Tweet media three

Tweet media four

5

9

41

@CovidAnalysis

Covid Analysis

4 years

Retrospective 396 patients in Iran, 93% using HCQ, showing HCQ mortality RR 0.45, p = 0.028. HCQ was the only antiviral that showed a significant difference. #c19study

Alamdari: Mortality Risk Factors among Hospitalized COVID-19 Patients in a Major Referral Center in...

Alamdari, 459 patient HCQ late treatment study: 55% lower mortality (p=0.03). Retrospective 459 patients in Iran with 93% treated with HCQ, showing HCQ..

2

25

41

@CovidAnalysis

Covid Analysis

4 years

90% reduction in cases with HCQ pre-exposure prophylaxis. 604 healthcare workers in India. Relative risk RR 0.10, p<0.0001

Tweet card media

Mathai: Hydroxychloroquine as pre-exposure prophylaxis against COVID-19 in health-care workers: A...

Mathai, 604 patient HCQ prophylaxis study: 90% fewer cases (p<0.0001). 90% reduction in cases with HCQ pre-exposure prophylaxis. Retrospective 604 healthcare..

0

14

37

@CovidAnalysis

Covid Analysis

4 years

41% reduction in cases with HCQ PEP, RR 0.59, p=0.03. Prospective, 132 HCQ/185 control. 50% reduction in PCR+ cases, 44% reduction in symptomatic cases. No serious adverse events. NCT04408456 doi:10.1016/j.ijantimicag.2020.106224

1

14

42

@CovidAnalysis

Covid Analysis

4 years

Retrospective 439 diabetic hospitalized patients showing 86% lower mortality with vitamin D >12.5 nmol/L, aHR 0.14, p = 0.007 (sufficiency analysis, not treatment, subject to confounding).

Alguwaihes: Diabetes and Covid-19 among hospitalized patients in Saudi Arabia: a single-centre...

Alguwaihes, 439 patient vitamin D sufficiency study: 86% lower mortality (p=0.007). Retrospective 439 diabetic hospitalized patients in Saudi Arabia showing..

2

13

39

@CovidAnalysis

Covid Analysis

6 months

The FDA’s recommendation against ivermectin on March 5, 2021 states that they did not review the data. They also claimed ivermectin is not antiviral, which is contradicted by extensive preclinical and clinical research. At the time there were 43 studies collectively showing

Tweet media one

Tweet media two

Tweet media three

4

20

40

@CovidAnalysis

Covid Analysis

4 years

Ivermectin prophylaxis and early treatment RCTs: 80% reduction in cases w/prophylaxis RR 0.2, p=0.03 89% reduction in mortality w/treatment RR 0.11, p=0.12 (non-severe); RR 0.1, p<0.001 (severe) doi:10.21203/rs.3.rs-100956/v1

Elgazzar: Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic

This study was withdrawn.

1

12

36

@CovidAnalysis

Covid Analysis

4 years

64% lower hospitalization with early HCQ. Retrospective 717 patients. aOR 0.32, p=0.00081, HCQ vs. no med. (RR 0.36) aOR 0.45, p=0.0065, HCQ vs. anything else

Tweet card media

Szente Fonseca: Risk of Hospitalization for Covid-19 Outpatients Treated with Various Drug Regimens...

Szente Fonseca, 717 patient HCQ early treatment study: 64% lower hospitalization (p=0.0008). 64% lower hospitalization with HCQ. Retrospective 717 patients in..

1

7

35

@CovidAnalysis

Covid Analysis

4 years

79% lower mortality and 82% lower hospitalization with early HCQ+AZ+Z. No cardiac side effects. Retrospective 518 patients. (journal version of earlier preprint)

Tweet card media

Derwand: COVID-19 Outpatients – Early Risk-Stratified Treatment with Zinc Plus Low Dose Hydroxych...

Derwand, 518 patient HCQ early treatment study: 79% lower mortality (p=0.12) and 82% lower hospitalization (p=0.001). 79% lower mortality and 82% lower..

2

14

33

@CovidAnalysis

Covid Analysis

11 months

Leaked documents show misconduct in the Together Trial. Marinos and Tallaksen report blinding was broken, with interim results shared externally with a group of 90+ people, many from other trials, in meetings organized by Dr. Andrew Hill. 1/

Tweet media one

2

13

39

@CovidAnalysis

Covid Analysis

4 years

Vitamin D studies for COVID-19. Most compare D levels with C19 risk, all are positive but this could be due to other factors correlated with vitamin D levels. However there are now 4 studies with active treatment, those are also all positive. #c19study

3

24

38

@CovidAnalysis

Covid Analysis

4 years

91% lower mortality with early outpatient HCQ, OR 0.092, p=0.001 (65 patients), and hospital use OR 0.737, p=0.36 (558 patients). Retrospective. Cyclosporine OR 0.24, p<0.001.

Tweet card media

Guisado-Vasco: Clinical characteristics and outcomes among hospitalized adults with severe COVID-19...

Guisado-Vasco, 607 patient HCQ late treatment study: 20% lower mortality (p=0.36). Retrospective 607 patients reporting results for early outpatient HCQ use..

2

13

36

@CovidAnalysis

Covid Analysis

4 years

52% lower mortality with HCQ. 2075 hospitalized patients in Spain, odds ratio 0.39, p<0.001, after adjustments (model 4). Ayerbe et al., doi:0.1007/s11739-020-02505-x

Ayerbe: The association of treatment with hydroxychloroquine and hospital mortality in COVID-19...

Ayerbe, 2,075 patient HCQ late treatment study: 52% lower mortality (p=0.001). 2075 hospital patients in Spain showing HCQ reduces mortality 52%, odds ratio..

2

13

33

@CovidAnalysis

Covid Analysis

11 months

Microbiome analysis shows a significant increase in the relative abundance of Bifidobacterium with ivermectin treatment. Increased abundance of Bifidobacterium is associated with lower COVID-19 severity. Bifidobacterium plays a key role in the immune system, for example

Tweet media one

7

10

38

@CovidAnalysis

Covid Analysis

1 year

We are working on an overview of the 3,000+ studies for 53 treatments analyzed to date. DM us if you can help with review.

2

12

35

@CovidAnalysis

Covid Analysis

4 years

The effects reported in all 21 COVID-19 HCQ Randomized Controlled Trials. Statistically significant effectiveness was reached on July 10. The 4 of 21 negative effects: very late use (3), excess dosage (2), baseline incomparable (1), very small (1).

1

12

35

@CovidAnalysis

Covid Analysis

1 year

Details for acetaminophen / paracetamol (Tylenol, Panadol, Calpol, Tempra, Calprofen, Doliprane, Efferalgan, Grippostad C, Dolo, Acamol, Fevadol, Crocin, and Perfalgan):

Tweet card media

Acetaminophen for COVID-19: real-time meta analysis of 27 studies

27 acetaminophen COVID-19 controlled studies. 28% increased risk, p < 0.0001.

2

8

35

@CovidAnalysis

Covid Analysis

4 years

37% lower mortality with HCQ+zinc. Retrospective 3,473 hospitalized patients. PSM aHR 0.63, p=0.015 regression aHR 0.76, p=0.023

1

11

30

@CovidAnalysis

Covid Analysis

4 years

Dramatic reduction in mortality, ventilation, and hospitalization (0 cases for all w/treatment) with early HCQ, ivermectin, and nitazoxanide. HCQ: mortality RR 0.17, p=0.21 ventilation RR 0.05, p=0.0008 hosp. RR 0.02, p<0.0001

Tweet card media

Cadegiani: Early COVID-19 Therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychlor...

Cadegiani, 296 patient HCQ early treatment study: 81% lower mortality (p=0.21), 95% lower ventilation (p=0.0008), and 98% lower hospitalization (p<0.0001)...

1

12

30

@CovidAnalysis

Covid Analysis

4 years

73% lower risk of COVID-19 with csDMARDs (HCQ-CQ-etc.) Analysis of 1641 systemic autoimmune disease patients showing csDMARD patients have 73% lower risk of COVID-19, p=0.015.

Tweet card media

Ferri: COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients...

Ferri, 1,641 patient HCQ prophylaxis study: 63% fewer cases (p=0.02). Analysis of 1641 systemic autoimmune disease patients showing csDMARD (HCQ etc.) RR 0.37..

1

12

35

@CovidAnalysis

Covid Analysis

7 months

Seifi et al.: lower COVID-19 hospitalization with higher zinc intake. Each unit increase in zinc intake was associated with a 31% reduction in the risk of COVID-19 hospitalization after adjustments.

Tweet media one

4

9

36

@CovidAnalysis

Covid Analysis

4 years

Malicious attack example of the day. SQL injection attempt to delete the database. 08/08/2020 22:11:50 <location redacted> { <connection trace redacted> } {'comment': "<redacted, modified for safe posting> DROP ALL TABLES;"}

8

8

29

@CovidAnalysis

Covid Analysis

4 years

Significantly lower mortality, HR 0.53 (CI 0.41–0.67). Retrospective 6,000 patients in NY. #COVID19

0

8

18

@CovidAnalysis

Covid Analysis

4 years

Tweet card media

Lagier: Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other...

Lagier, 3,737 patient HCQ late treatment study: 59% lower mortality (p=0.05). Early treatment leads to significantly better clinical outcome and faster viral..

3

17

23

@CovidAnalysis

Covid Analysis

4 years

Ivermectin+doxycycline RCT showing significant improvements in recovery (45%), progression (55%), and virological cure (42%). No deaths with treatment versus 3 deaths in the control group (183 and 180 total patients respectively). NCT04523831

Mahmud: Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized...

Mahmud, 366 patient ivermectin early treatment RCT: 86% lower mortality (p=0.25), 57% lower progression (p=0.001), 94% improved recovery (p<0.0001), and 39%..

2

16

31

@CovidAnalysis

Covid Analysis

4 years

Analysis of HCQ dosing, suggesting high initial doses followed by low sparse doses may better decrease viral load while also avoiding levels considered to produce adverse effects. #c19study Karatza et al., Xenobiotica, doi:10.1080/00498254.2020.1824301

Karatza: Optimization of hydroxychloroquine dosing scheme based on COVID-19 patients’ characteris...

Analysis of HCQ dosing, suggesting that high initial doses followed by low and sparse doses may offer significant benefits to patients by decreasing the viral..

2

17

27

@CovidAnalysis

Covid Analysis

4 years

Vitamin D3 supplementation during or just before C19 associated with 68% lower mortality and less severe cases. Retrospective 66 nursing home residents, mean age 88, oral bolus 80,000IU D3, 5 of 9 control deaths, 10 of 57 treatment

Annweiler: Vitamin D and survival in COVID-19 patients: A quasi-experimental study

Annweiler, 66 patient vitamin D early treatment study: 89% lower mortality (p=0.002). Vitamin D3 supplementation during or just before COVID-19 was associated..

1

17

31

@CovidAnalysis

Covid Analysis

1 year

411th controlled study of HCQ for COVID-19, finding that HCQ+AZ treatment was safe and associated with significantly lower mortality. Publication was delayed over 3 years. As of 2001, the paper had been rejected by the editors of four different journals, all without peer review.

Tweet media one

Tweet media two

2

12

33

@CovidAnalysis

Covid Analysis

1 year

We are working on an overview of the 2,900+ studies analyzed to date. DM us if you are a scientist working in the area and can help with review.

2

5

28

@CovidAnalysis

Covid Analysis

7 months

@GidMK The PRINCIPLE trial shows significantly faster recovery and significantly lower long COVID with ivermectin. We also know, from all trials for the 66 treatments we analyze, that improved recovery is very strongly associated with lower mortality (p<0.000000001). 36% lower ongoing

Tweet media one

7

6

32

@CovidAnalysis

Covid Analysis

4 years

@drdavidsamadi Now 177 HCQ controlled studies, meta analysis: early treatment - 65% improvement, p < 0.0001 all studies - 33% improvement, p < 0.0001

1

6

24

@CovidAnalysis

Covid Analysis

4 years

Small prophylaxis study showing 57% lower cases with HCQ, p = 0.03. Actual benefit could be larger because the control group had lower risk. Polat et al., Medical Journal of Bakirkoy, 16:3, 280-6, doi:10.5222/BMJ.2020.50469

Tweet card media

Polat: Hydroxychloroquine Use on Healthcare Workers Exposed to COVID-19 - A Pandemic Hospital...

Polat, 208 patient HCQ prophylaxis study: 57% fewer cases (p=0.03). Small prophylaxis study of 208 healthcare workers in Turkey, 138 with high risk exposure..

1

13

24

@CovidAnalysis

Covid Analysis

4 years

73% reduction in mortality with HCQ+AZ, adjusted HR 0.27 [0.17-0.41]. Retrospective 377 patients, mean age 71.8. #c19study

Tweet card media

Lauriola: Effect of combination therapy of hydroxychloroquine and azithromycin on mortality in...

Lauriola, 360 patient HCQ late treatment study: 74% lower mortality (p=0.001). Retrospective 377 patients, 73% reduction in mortality with HCQ+AZ, adjusted..

0

17

26

@CovidAnalysis

Covid Analysis

7 months

Oxford COPCOV trial: "We are in a race against time to find effective treatments and preventive measures". COPCOV treatment 1: results still secret >700 days. PRINCIPLE treatment 1: results still secret >1,350 days. PRINCIPLE treatment 2: results showing significantly lower

@sudokuvariante

Fred Stalder

@sudokuvariante

7 months

The accelerated schedule of @UniofOxford is a weird notion. After ivermectin principle trial publication delayed by 19 months, we still wait for the results of COPCOV trial...

2

3

15

1

12

31

@CovidAnalysis

Covid Analysis

4 years

Analysis of Boulware et al. PEP trial: . COVID cases reduced by [49%, 29%, 16%] respectively when taken within [2+, 3+, 4+] days of exposure.

COVID-19 Treatment Analysis: Boulware et al. NEJM Analysis

Boulware et al. NEJM Analysis - COVID cases are reduced by [49%, 29%, 16%] respectively when taken within [2+, 3+, 4+] days of exposure.

4

12

20

@CovidAnalysis

Covid Analysis

4 years

Chronic treatment provides protection against COVID, odds ratio 0.51 (0.37-0.70) #COVID19

Tweet card media

Ferreira: Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection [HCQ]

Ferreira, 26,815 patient HCQ prophylaxis study: 47% fewer cases (p<0.0001). Chronic treatment with HCQ provides protection against COVID, odds ratio 0.51 (0..

3

13

17

@CovidAnalysis

Covid Analysis

4 years

Ivermectin RCT showing a correlation between plasma concentration and viral decay rate (r=0.46, p=0.02). Significantly faster viral decay with higher median plasma levels (0.64 vs 0.13, p=0.011). Krolewiecki et al.

1

12

27

@CovidAnalysis

Covid Analysis

4 years

HCQ lung pharmacokinetic study confirming that lung concentrations can be much higher than plasma. Median lung epithelial lining fluid concentration 38x plasma concentration.

Ruiz: Hydroxychloroquine lung pharmacokinetics in critically ill patients infected with COVID-19...

HCQ lung pharmacokinetic study confirming that lung concentrations can be much higher than plasma and exceed predicted EC50 values. The median lung epithelial..

1

7

22

@CovidAnalysis

Covid Analysis

4 years

A video history of the 126 HCQ studies to date. The probability that the results are from an ineffective treatment is estimated to be 1 in 69 million (p = 0.000000015). p < 0.01 was reached on May 18. #hcqmeta

0

8

25

@CovidAnalysis

Covid Analysis

7 months

In 2021 Naggie et al. showed that HCQ pre-exposure prophylaxis significantly reduces COVID-19 cases based on 2 US RCTs: OR 0.74, p = 0.046 How about now? 13 RCTs showing: RR 0.71, p = 0.00023 How about non-RCT studies? RR 0.71, p = 0.000000013 14 RCTs have not reported

Tweet media one

Tweet media two

Tweet media three

2

9

26

@CovidAnalysis

Covid Analysis

4 years

100 patient prospective trial of ivermectin + doxycycline showing 21% faster recovery. Spoorthi et al., IAIM, 2020, 7:10, 177-182

Spoorthi: Utility of Ivermectin and Doxycycline combination for the treatment of SARSCoV-2

Spoorthi, 100 patient ivermectin late treatment study: 21% faster recovery (p=0.03) and 16% shorter hospitalization (p=0.01). 100 patient prospective trial of..

0

5

22

@CovidAnalysis

Covid Analysis

4 years

Retrospective rheumatic condition patients showing zero mortality with HCQ, odds ratio OR 0.0, p=0.10. HCQ mortality 0 of 10,703 vs. control 7 of 21,406. COVID-19 cases OR 0.79, p=0.27 #c19study

Tweet card media

Gentry: Long-term hydroxychloroquine use in patients with rheumatic conditions and development of...

Gentry, 32,109 patient HCQ prophylaxis study: 91% lower mortality (p=0.1) and 21% fewer cases (p=0.27). Retrospective patients with rheumatologic conditions..

4

13

22

@CovidAnalysis

Covid Analysis

1 year

Vitamin D treatment shows reduced risk for COVID-19 (p<0.0000000001) Acetaminophen / paracetamol shows increased risk (p=0.0000018) Which of these was recommended for COVID-19 by authorities in your area:

Vitamin D

24

Acetaminophen

134

Neither

262

Both

11

2

8

26

@CovidAnalysis

Covid Analysis

6 months

Details:

Tweet card media

Azhar: Effectiveness of early pharmaceutical interventions in symptomatic COVID-19 patients: A...

Azhar, 471 patient HCQ early treatment RCT: 71% lower mortality (p=0.03), 4% greater improvement (p=0.64), and 10% improved viral clearance (p=0.52). RCT 471..

3

6

24

@CovidAnalysis

Covid Analysis

4 years

6th independent analysis showing efficacy from the Boulware PEP trial. Prospective analysis correcting an error in the NEJM paper where shipping delays are omitted. RR 0.58, p = 0.04, for the original trial 3 day specification.

0

6

23

@CovidAnalysis

Covid Analysis

4 years

pneumonia, ↓68.4%, p=0.21 Small low dose HCQ trial w/low risk HCW, 68% lower pneumonia, p=0.21; median viral clearance 15 days HCQ vs. 22 days control.

Tweet card media

Agusti: Efficacy and safety of hydroxychloroquine in healthcare professionals with mild SARS-CoV-2...

Agusti, 142 patient HCQ early treatment study: 68% lower progression (p=0.21) and 32% faster viral clearance. Small trial of low dose HCQ for healthcare..

1

11

21

@CovidAnalysis

Covid Analysis

4 years

them: "Nature lung" paper proves it can't work us: 1. efficacy at higher conc., stat. sig. issues 2. ignores theories of action 3. Calu-3 from lung adenocarcinoma; resembles serous cells; good for forming tumors; isolated, lacks many factors them:

0

8

18

@CovidAnalysis

Covid Analysis

4 years

Review of zinc as an inhibitor of SARS-CoV-2′s RNA-dependent RNA polymerase, and zinc ionophores including CQ/HCQ, showing the latest evidence for zinc and CQ/HCQ having antiviral, and in particular anticoronaviral action. #c19study

0

16

24